As regulatory expectations evolve, manufacturers are looking for smarter ways to validate software used in production and quality systems. The FDA’s Computer Software Assurance for Production and Quality System Software (CSA) guidance modernizes the approach to validation by emphasizing risk-based thinking, intended use, and least-burdensome assurance activities.

At InstantGMP, we’ve aligned our software development and validation practices with these principles—not only to maintain compliance, but to give our customers greater confidence in how their systems perform.

In this blog, we break down how InstantGMP incorporates CSA guidance into our validation process and what this means for our users.

Understanding CSA: A Shift from Traditional CSV

For years, computer system validation (CSV) relied heavily on exhaustive scripted testing and documentation. While effective, this approach was often time-consuming and did not distinguish between low- and high-risk features.

The FDA’s CSA guidance updates this mindset by recognizing that not all software functions carry the same level of risk. Instead, companies should base their validation efforts on the process risks associated with each feature:

• Could the software failure compromise production?
• Could it negatively impact the quality system?
• Could it affect data integrity or regulatory decision-making?

Unlike medical device software, InstantGMP’s software is not classified as a device or part of a device. Therefore, our focus is strictly on process risks, not patient-safety risks.

InstantGMP’s Process-Risk Evaluation Framework

InstantGMP analyzes every module and function within our system to determine the level of process risk it presents. This assessment determines the rigor of validation activities and ensures resources are focused where they matter most.

Low Process-Risk Features- these functions collect or tabulate data and do not directly control production decisions or impact quality-system outcomes.

Examples include:

• Equipment Logs
• Room Logs
• Deviation Logs
• CAPA Logs

Even if these features were to fail temporarily, there is no foreseeable impact on product quality or regulatory compliance—making them low risk under CSA.

Moderate Process-Risk Features

These features support production and quality workflows but cannot execute without human oversight. Examples include:

• Inventory adjustments
• Batch record data-entry steps
• Quality reviews and approvals

Because these functions require user confirmation and authenticated signatures, FDA does not classify them as high risk.

High Process-Risk Features (Not Present in iGMP)

High-risk features would be those that:

• Automatically perform actions without user approval
• Make decisions that could directly impact quality or safety

InstantGMP does not include any autonomous or decision-making features of this kind. Every regulated action within the system requires an authenticated, traceable, human review.

User Oversight Enables Risk Reduction

A core principle within InstantGMP’s design is that no system action can occur without user intervention. This ensures:

• Role-based control over every action
• Electronic signatures for approvals
• Comprehensive audit trails
• Prevention of unauthorized changes

This oversight dramatically lowers process risk and aligns with CSA’s principle that human approval mitigates automation risks.

Applying FDA’s “Least Burdensome” Approach—But Going Beyond It

FDA’s CSA guidance allows the use of less burdensome assurance activities for low- and moderate-risk features, including:

• Exploratory testing
• Non-scripted testing
• Supplier documentation
• Audit trails as objective evidence
• Automated execution tools

However, InstantGMP intentionally goes beyond FDA’s minimum guidance.

Our Validation Approach Includes:

• Scripted qualification testing for all features
• Automated execution using GXtest
• Full requirements traceability
• Validation Summary Reports for each release
• Documentation managed through a controlled DMS

This ensures reproducibility, transparency, and a defensible validation package for regulatory inspections.

Why This Matters for InstantGMP Customers

By incorporating CSA while maintaining a high level of testing rigor, InstantGMP provides:

✔ Stronger Compliance Assurance

All system enhancements and releases include full OQ execution and documented validation results.

✔ Reduced Validation Burden for Clients

Our hosted platform allows the majority of validation to be completed by InstantGMP—accelerating customer implementation timelines.

✔ Improved Traceability and Audit Readiness

Every requirement, test, and approval is linked electronically, ensuring clean, well-organized documentation for audits.

✔ Confidence in System Reliability

Customers know that every feature—from low-risk logs to core production workflows—has been evaluated and tested appropriately.

Conclusion

InstantGMP’s adoption of FDA’s Computer Software Assurance principles reflects our commitment to innovation, compliance, and customer success. While CSA encourages a more flexible and less burdensome approach, we choose to pair its risk-based methodology with high-rigor testing and validation practices.

This balanced approach ensures that InstantGMP software remains both compliant and reliably validated, supporting every step of our customers’ production and quality operations.